CKB and osteosarcoma: We also extend our analysis to other metastatic cell lines, such as OVCAR8 (high-grade serous ovarian cancer) (47) and 143B (osteosarcoma) (54), both of which we show rely on CKB for CK activity, making them susceptible to CK-targeting therapies.